DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

DRG
  • Login
  • Products
    • Biopharma
      • Market Assessment
      • Multichannel Engagement Insights
      • Real-World Data
      • Market Access

      • Fingertip Formulary Suite
      • Managed Market Surveyor
      • Account Management Dashboard
      • U.S. Managed Markets Insights
      • Healthbase
      • Market Access Platform
      • Global Market Access Solution
    • Medtech
      • Market Insights
      • Procedure Finder
      • PriceTrack
  • Solutions
    • Solutions
      • Market Sizing and Forecasting
      • Commercial Effectiveness
      • Global Access Solutions
      • Multichannel Engagement Strategy
      • Integrated Patient Journey
      • Understanding Covered Lives
      • Learning Solutions
      • Biotech solutions
      • Medtech Solutions
      • Payer Solutions
      • Provider Solutions
    • Consulting Services
      • Consulting Services
      • HEOR & Value Communication
  • Find A Report
    • Market Assessment
    • Multichannel Engagement
    • Market Access
    • Medtech Insights
  • Events
    • Meet Us at These Events
  • DRG Perspectives
  • About Us
    • Our Company
    • About Clarivate
    • Newsroom
    • Careers
    • Contact us

DRG and its group companies would like to inform you that we have updated our website privacy policy.

Acknowledge
Home › DRG Perspectives › AbbVie's Acquisition of Allergan -...
Medtech Market Trends Series
AbbVie’s Acquisition of Allergan

AbbVie to acquire Allergan for $63 billion: a potential boost for an aesthetics giant

Our aesthetics experts give their take on how this move will impact Allergan and the broader market:

Why is AbbVie Acquiring Allergan?

  • AbbVie’s US patent for Humira—its lucrative drug for arthritis, psoriasis, and other conditions—expires in 2023, and without a similar blockbuster drug of this magnitude in its portfolio on the horizon, the company needs to make a move to drive long-term growth.
  • AbbVie’s choice of Allergan represents a step for AbbVie to reduce its reliance on Humira and expand and diversify its portfolio.
  • While AbbVie is paying a premium price to acquire Allergan, the company is still a reasonably valued purchase because of a sizable drop in Allergan’s valuation from its peak 4 years ago.

Allergan’s Profile

  • Allergan’s medical aesthetics portfolio yields an annual revenue of roughly $4.3 billion in the high-growth global aesthetics space. Its stronghold in this market mainly stems from its BOTOX product—the leading cosmetic botulinum toxin worldwide, offering Allergan significant brand value.
  • Although a lower-priced, similar efficacy competing product from Evolus has been recently approved in the US and another from Revance with compelling data is on its way, BOTOX has the upper hand in terms of brand recognition and is positioned to continue to yield strong, durable growth for the company in the country over the next decade.

How Will This Impact Allergan?

  • From Allergan’s perspective, this presents an opportunity to strengthen its leadership position in the quickly expanding aesthetics market and drive incremental growth by leveraging AbbVie ’s strong commercial capabilities and broad global infrastructure.
  • With the resources and capabilities of its new parent company, Allergan may also be able to drive further innovation with BOTOX, including the development of new indications, formulations, configurations, and delivery technologies.
  • The company could also venture into developing next-generation products in its JUVÉDERM line of dermal fillers and will be better equipped to enhance its CoolSculpting technology, with 3 upgrades—for muscle conditioning, skin tightening, and cellulite breakthrough—already planned for the next 3 years.
  • Both Allergan and AbbVie also have overlap in products for treatments in women’s health, gastrointestinal diseases, and other disorders, allowing for some synergies between the two companies. Allergan also has the potential to expand its customer base as a result.

What Competitors Should Keep An Eye On

  • Will this acquisition prove to be disruptive to Allergan’s business as its operations merge with AbbVie’s, and will this open up inroads for other competitors?
  • How will this change Allergan’s strategic direction going forward? What implications will it have on pricing strategies and product development?
  • Are other acquisitions on the horizon?

Related coverage:

Read how the acquisition will impact Allergan’s CNS and Ophthalmology’s businesses

Stay up-to-date with the latest in the aesthetics space

Robert Cohen

Aesthetics Expert

Robert specializes in the fields of aesthetic injectables and cosmetic threads. Robert holds an Honors Bachelor's degree in Immunology from McGill University.

Recent article

Evolus Set to Enter the Aesthetic Botulinum Toxin Market – How will Competitors React?

Additional contributors: Raghav Tangri, Diwakar Bahuguna

Contact questions@teamdrg.com with your questions and data requests:

  • Aesthetic Energy-Based Devices
  • Aesthetic Injectables
  • Breast Implants and Reconstructive Devices
  • Cosmetic Threads
  • Physician-Dispensed Cosmeceuticals
  • US, European, Asia Pacific, and Latin American market forecasts predicting what the future holds in this space
  • Market sizing
  • Pricing analysis
  • Patient journey and subpopulation analysis
  • Customer segmentation and targeting
  • Patient multichannel engagement strategies

Here are a few reasons leading medtech companies say they partner with us over other vendors:

  • Industry’s most comprehensive and accurate data stack, covering 1,900 facilities and 12.6 billion patient claims
  • Subject matter experts across 50+ markets and data scientists to vet and triangulate multiple data sources for contextually-driven intelligence
  • Complete transparency into the sources and methodologies of our insights
  • Prompt answers to client questions and collaborative sessions to help maximize services
  • End-to-end medtech commercial solutions spanning data, on-demand intelligence, custom research and analytics, advisory services, and training

Get the latest data and expert perspectives on the aesthetics market

Get content updates to your inbox

Subscribe

MedTech Infographics

A Look Ahead: Medical Aesthetics Market Recovery in 2021 and Beyond

View Now
DRG

Decision Resources Group

DRG is the premier provider of healthcare analytics, data and insight products and services to the world’s leading pharma, biotech and medical technology companies.

Read More

Company

  • About DRG
  • Careers
  • Offices
  • Locations

Resources

  • Sitemap
  • Newsroom
  • Whitepapers
  • Events
  • Reports

Support

  • Client Portal

Social

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Contact Us
  • Privacy & Cookies
  • Term of Use
  • Privacy Center
  • 2020 DR/Decision Resources, LLC
  • Find a Report
  • Linkedin
  • Twitter
  • Contact Us
Thank you for your ebook download,
and live webinar registration.

Don’t forget to attend on Jan. 19!

Close